Mechanisms for the development of heart failure and improvement of cardiac function by angiotensin-converting enzyme inhibitors
Authors:
- Sukhwinder K. BhullarSBSukhwinder K. Bhullar
- Anureet K. ShahASAnureet K. Shah
- Naranjan S. DhallaNDNaranjan S. Dhalla
Open Access
- 1 January 2022
- journal article
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 53 (1) , 51-76
Abstract
Angiotensin-converting enzyme (ACE) inhibitors, which prevent the conversion of angiotensin I to angiotensin II, are well-known for the treatments of cardiovascular diseases, such as heart failure, hypertension and acute coronary syndrome. Several of these inhibitors including captopril, enalapril, ramipril, zofenopril and imidapril attenuate vasoconstriction, cardiac hypertrophy and adverse cardiac remodeling, improve clinical outcomes in patients with cardiac dysfunction and decrease mortality. Extensive experimental and clinical research over the past 35 years has revealed that the beneficial effects of ACE inhibitors in heart failure are associated with full or partial prevention of adverse cardiac remodeling. Since cardiac function is mainly determined by coordinated activities of different subcellular organelles, including sarcolemma, sarcoplasmic reticulum, mitochondria and myofibrils, for regulating the intracellular concentration of Ca2+ and myocardial metabolism, there is ample evidence to suggest that adverse cardiac remodelling and cardiac dysfunction in the failing heart are the consequence of subcellular defects. In fact, the improvement of cardiac function by different ACE inhibitors has been demonstrated to be related to the attenuation of abnormalities in subcellular organelles for Ca2+-handling, metabolic alterations, signal transduction defects and gene expression changes in failing cardiomyocytes. Various ACE inhibitors have also been shown to delay the progression of heart failure by reducing the formation of angiotensin II, the development of oxidative stress, the level of inflammatory cytokines and the occurrence of subcellular defects. These observations support the view that ACE inhibitors improve cardiac function in the failing heart by multiple mechanisms including the reduction of oxidative stress, myocardial inflammation and Ca2+-handling abnormalities in cardiomyocytes.Keywords
This publication has 373 references indexed in Scilit:
- Recent advances involving the renin–angiotensin systemExperimental Cell Research, 2012
- Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia–reperfusion induced infarct sizeCytokine, 2011
- Ryanodine Receptor Oxidation Causes Intracellular Calcium Leak and Muscle Weakness in AgingCell Metabolism, 2011
- Left Ventricular Dysfunction in Murine Models of Heart Failure and in Failing Human Heart is Associated With a Selective Decrease in the Expression of Caveolin-3Journal of Cardiac Failure, 2011
- Angiotensin II receptors and drug discovery in cardiovascular diseaseDrug Discovery Today, 2011
- The ups and downs of mitochondrial calcium signalling in the heartBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2010
- Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunctionAmerican Heart Journal, 2009
- Troponin phosphorylation and myofilament Ca2+-sensitivity in heart failure: Increased or decreased?Journal of Molecular and Cellular Cardiology, 2008
- Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in ratsLife Sciences, 2006
- Captopril Treatment Improves the Sarcoplasmic Reticular Ca2+Transport in Heart Failure Due to Myocardial InfarctionJournal of Molecular and Cellular Cardiology, 1999